Anti-Restenosis After AMI by Erythropoietin

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute myocardial infarction

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyoto Prefectural University of Medicine
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Clinical diagnosis of acute myocardial infarction within 12hrs of symptom onset.

• Succeeded reperfusion due to primary PCI accomplished bare metal stent

Exclusion Criteria:

• Patients with cardiogenic shock (e.g. systolic BP<80mmHg,use of catecholamine, use of IABP)

• Patients with anemia required transfusion

• Patients who are unwilling or unable to comply with the trial protocol